Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group- specific Antigen ("Gag") protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.